NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.19 +0.24 (+0.30%) GOLD FUTURES
2,313.30 +3.70 (+0.16%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,245.83 +1,149.73 (+2.49%)
FibroGen, Inc. (FGEN)
After hours:
| Previous close | 1.1700 |
| Open | 1.1900 |
| Bid | 1.1100 x 1000 |
| Ask | 1.1400 x 1000 |
| Day's range | 1.1200 - 1.2300 |
| 52-week range | 0.3330 - 19.4700 |
| Volume | |
| Avg. volume | 1,992,698 |
| Market cap | 112.406M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9200 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.75 |
GlobeNewswireFibroGen to Report First Quarter 2024 Financial Results
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the
- GlobeNewswire
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois. Details for the poster presentation are as foll
ZacksVertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
